Erythropoietin Potentiates the Anti-proliferative Effect of Tamoxifen in Ovarian Adenocarcinoma A2780 Cells

Authors

  • Patrícia Kimáková Department of Cell Biology, Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice
  • Erika Szentpéteriová Department of Cell Biology, Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice
  • Barbora Fecková Department of Cell Biology, Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice
  • Nataša Debeljak Institute of Biochemistry, Faculty of Medicine, University of Ljubljana
  • Peter Solár Department of Medical Biology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice

DOI:

https://doi.org/10.17344/acsi.2018.4452

Keywords:

Erythropoietin receptor, erythropoietin, tamoxifen, A2780, cancer cell line

Abstract

We have recently shown that erythropoietin receptor (EPOR) protects cancer cells from tamoxifen (TAM)-induced cell death in the absence of erythropoietin (EPO). In this study, we analyzed the effect of EPOR silencing and EPO treatment on the response to TAM in human ovarian adenocarcinoma cells A2780. We demonstrated that the EPOR siRNA silencing decreases cell proliferation and sensitizes and/or potentiates the anti-proliferative effect of TAM on A2780 cells. Similarly, the combined effect of EPO and TAM treatment significantly reduced cell proliferation compared to TAM alone. Our in vitro results indicated the need for further investigation of EPO effects on a similar in vivo model.

Downloads

Additional Files

Published

14.12.2018

Issue

Vol. 65 No. 4 (2018)

Section

Biomedical applications

License

Except where otherwise noted, articles in this journal are published under the Creative Commons Attribution 4.0 International License